Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
Abiraterone Acetate
Anti-Cancer/ Oncology
Acalabrutinib
Anti-Cancer/ Oncology
Adagrasib
Anti-Cancer/ Oncology
Apalutamide (Amorphous & Form B)
Anti-Cancer/ Oncology
Azacitidine
Anti-Cancer/ Oncology
Bendamustine Hydrochloride
Anti-Cancer/ Oncology
Bortezomib
Anti-Cancer/ Oncology
Cabazitaxel
Anti-Cancer/ Oncology
Cabozantinib HCl
Anti-Cancer/ Oncology
Cabozantinib S-Malate
Anti-Cancer/ Oncology
Capecitabine
Anti-Cancer/ Oncology
Carfilzomib
Anti-Cancer/ Oncology
Darolutamide
Anti-Cancer/ Oncology
Dasatinib (Monohydrate)
Anti-Cancer/ Oncology
Decitabine
Anti-Cancer/ Oncology
Deucravacitinib
Anti-Cancer/ Oncology
Enzalutamide
Anti-Cancer/ Oncology
Eribulin (Available For Selected Markets)
Anti-Cancer/ Oncology
Fosaprepitant
Anti-Cancer/ Oncology
Fruquintinib
Anti-Cancer/ Oncology
Gemcitabine Hydrochloride
Anti-Cancer/ Oncology
Granisteron
Anti-Cancer/ Oncology
Lenalidomide (Form A)
Anti-Cancer/ Oncology
Lenvatinib Mesylate ( MIBK Solvate)
Anti-Cancer/ Oncology
Lenvatinib Mesylate (Form-C)
Anti-Cancer/ Oncology
Lomustine
Anti-Cancer/ Oncology
Midostaurin
Anti-Cancer/ Oncology
Nilotinib Hydrochloride Monohydrate (Form B)
Anti-Cancer/ Oncology
Niraparib Tosylate
Anti-Cancer/ Oncology
Olaparib (Form A)
Anti-Cancer/ Oncology
Palbociclib
Anti-Cancer/ Oncology
Pazopanib
Anti-Cancer/ Oncology
Pemetrexed Disodium Heptahydrate
Anti-Cancer/ Oncology
Pirtobrutinib
Anti-Cancer/ Oncology
Pomalidomide
Anti-Cancer/ Oncology
Relugolix
Anti-Cancer/ Oncology
Ripretinib
Anti-Cancer/ Oncology
Ritlecitinib
Anti-Cancer/ Oncology
Ruxolitinib Phosphate
Anti-Cancer/ Oncology
Tucatinib
Anti-Cancer/ Oncology
Venetoclax
Anti-Cancer/ Oncology
Zanubrutinib
Anti-Cancer/ Oncology
Zoledronic Acid
Anti-Cancer/ Oncology
Oncology/Anticancer API Products Manufacturer and Supplier
Dr. Reddy's is a global leader in developing APIs in the Oncology/Anti-cancer therapy area, with deep technical and scientific knowledge established over decades. With a strong presence across six continents and 39 countries, we are a partner of choice for supplying APIs to leading oncology formulators globally.
As one of the largest generic pharmaceutical manufacturers in the world, we have established a niche in generic oncology APIs and partner of choice for supplying APIs to leading oncology formulators globally.
Our various classes of API under anti-cancer portfolio are as follows:
Kinase Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
BCL-2 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Androgen Receptor (AR) Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Folate Analog Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Microtubule Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Proteasome Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Thalidomide Analogue
*Countries referred in the above graphic denotes DMF filing geographies
CYP17 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Bifunctional Mechlorethamine
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Alkylating Agent
*Countries referred in the above graphic denotes DMF filing geographies
Poly (ADP-ribose) Polymerase
*Countries referred in the above graphic denotes DMF filing geographies
CXCR4 Chemokine Receptor
*Countries referred in the above graphic denotes DMF filing geographies
GnRH Receptor Antagonist
*Countries referred in the above graphic denotes DMF filing geographies
Chemical Permeation Enhancer
*Countries referred in the above graphic denotes DMF filing geographies
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
USPs of our Anti-cancer APIs
- QbD approach for an efficient process & high-quality output
- Availability of APIs in various forms.
- cGMP API manufacturing facility - Successfully inspected by international regulatory authorities.
- GTIs & impurities are controlled below the TTC limit & ICH limits, respectively.
- Formulation dossier filed across all major markets.
- Regulatory filing available across the globe.
- Completely backward integrated on the Key starting materials to ensure uninterrupted supplies.
- Adequate capacity to meet the global demands.
- KSM suppliers with timely deliveries and adherence to stringent specifications.
- Process safety management guidelines are implemented to enable a sustainable product supply.
- IP-Compliant API that meets regulatory requirements.
Disclaimer
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.